Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6] Core Views - The company's Q1 2025 performance met expectations, with revenue of 3.241 billion yuan, a year-on-year increase of 2.04%, and a net profit attributable to shareholders of 435 million yuan, a slight increase of 1.35% [1] - The industry is gradually stabilizing, and the company experienced good sales growth in Q1, particularly in its raw materials business, which was the main driver of revenue growth [1][2] - The company maintained good cost control, with a reduction in total expenses compared to the previous year, positively impacting net profit [3] - The company is advancing its projects in Liaoning, which are expected to optimize product layout and create new growth points for sustainable development [3] Financial Summary - For 2025-2027, the projected net profit attributable to the parent company is expected to be 1.47 billion yuan, 1.78 billion yuan, and 2 billion yuan respectively, reflecting a positive growth outlook [3] - The company's revenue for 2025 is estimated at 12.86 billion yuan, with a growth rate of 23.23% compared to 2024 [5] - The earnings per share (EPS) for 2025 is projected to be 3.61 yuan, with a price-to-earnings (P/E) ratio of 14.44 [5] Sales and Pricing - In Q1, the company achieved sales volumes of 28,700 tons for raw materials and 15,400 tons for formulations, representing increases of 14.8% and 2.8% year-on-year respectively [2] - The average prices for raw materials and formulations in Q1 were 63,000 yuan and 56,600 yuan, showing declines of 8.8% and 1.6% year-on-year [2] Cost Control and Project Development - The company reduced its sales expenses by approximately 1.65 million yuan year-on-year, while management and R&D expenses increased [3] - The first phase of the Liaoning project has been completed and is in the process of trial production, with several products already meeting quality standards [3]

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 56.61 [8][9]. Core Views - The final ruling on anti-dumping measures against imported chlorpyrifos from India is expected to boost domestic prices, which have been low for a long time. This is anticipated to positively impact the company's growth prospects, particularly with the Huludao project, leading to a gradual recovery in industry conditions [1][3]. - The company has reported a significant increase in the average market prices of its main products as of May 8, 2025, indicating a potential upward trend in profitability [3]. - The company's Huludao project is progressing well, with construction completed ahead of schedule, which is expected to contribute positively to future profits [4]. Summary by Sections Anti-Dumping Measures - The Ministry of Commerce announced the final ruling on anti-dumping investigations against imported chlorpyrifos from India, with anti-dumping duties ranging from 48.4% to 166.2% to be implemented for five years starting May 7, 2025. This is expected to alleviate price suppression from imports [1][2]. Price Trends and Market Conditions - The average market prices for key products such as high-efficiency fluorochlorpyrifos and others have shown slight increases compared to early 2025, suggesting a potential recovery in the agricultural chemical market [3]. Project Development - As of the first quarter of 2025, the company has reported ongoing construction projects valued at RMB 1.76 billion, with the Huludao project expected to enhance profitability as production ramps up [4]. Financial Forecasts - The company forecasts net profits of RMB 1.35 billion, RMB 1.55 billion, and RMB 1.75 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 13%, 15%, and 13% [5][7]. - Earnings per share (EPS) are projected to be RMB 3.33, RMB 3.81, and RMB 4.31 for the same years [5][7]. Valuation Metrics - The company is assigned a price-to-earnings (P/E) ratio of 17 times for 2025, based on comparable company analysis, leading to a target price of RMB 56.61 [5][9].

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of 56.61 RMB [8][9]. Core Views - The final ruling on anti-dumping measures against imported chlorpyrifos from India is expected to boost domestic prices, which have been low for a long time. The anti-dumping duties range from 48.4% to 166.2% [1][2]. - The company's Huludao project is anticipated to contribute positively to profits as it progresses, with a reported construction cost of 1.76 billion RMB as of Q1 2025 [4]. - The overall pesticide industry is expected to gradually recover, with prices for key products like chlorpyrifos and bifenthrin showing signs of increase [3]. Summary by Sections Investment Rating - The company is rated "Buy" with a target price of 56.61 RMB, reflecting a positive outlook based on industry recovery and company growth potential [8]. Industry Overview - The anti-dumping ruling is expected to alleviate price suppression caused by imports from India, which accounted for 71% of domestic demand in recent years [2]. - The average prices for various pesticide products are projected to rise, indicating a potential recovery in the agricultural chemicals sector [3]. Company Performance - The company’s net profit forecasts for 2025-2027 are 1.35 billion, 1.55 billion, and 1.75 billion RMB, respectively, with a year-on-year growth of 13% to 15% [5]. - The EPS for the same period is projected to be 3.33, 3.81, and 4.31 RMB, indicating a steady increase in earnings per share [5]. Project Development - The Huludao project is progressing efficiently, with the first phase completed ahead of schedule, which is expected to enhance the company's profitability in the future [4].